Nura Bio closes further financing; names new CEO

US clinical-stage biotech Nura Bio today closed announced a more than $140 million in Series A financing.

This includes the addition of $68 million to the initial Series A round of $73 million which was in 2020. The round was led by founding investor the Column Group, with participation from continuing investors Samsara Bio Capital and Euclidean Capital, and new investor Sanofi Ventures.

The company also announced the appointment of Shilpa Sambashivan as chief executive (CEO) and a company director. As a member of the founding team at Nura Bio and chief scientific officer (CSO) Dr Sambashivan has been the driving force behind Nura Bio’s bespoke research engine and differentiated R&D pipeline, with the company’s first clinical candidate, NB-4746, recently completing Phase I studies in healthy volunteers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK